Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Double-blind, Randomized, Placebo-Controlled Study to Assess the Efficacy and Safety of TX000045 After 24 Weeks of Treatment in Patients With Pulmonary Hypertension Secondary to Heart Failure With Preserved Ejection Fraction (PH-HFpEF)

NCT06616974 is registered in ClinicalTrials.gov with Tectonic Therapeutic as lead sponsor.

NCT NCT06616974
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06616974 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Double-blind, Randomized, Placebo-Controlled Study to Assess the Efficacy and Safety of TX000045 After 24 Weeks of Treatment in Patients With Pulmonary Hypertension Secondary to Heart Failure With Preserved Ejection Fraction (PH-HFpEF)
Lead sponsor
Tectonic Therapeutic
Phase
Phase 2
Overall status
Active, not recruiting
Start date
September 4, 2024
Completion date
January 5, 2027
Enrollment
191 (estimated)
Sites
72

Conditions

As the registry lists them; a condition with its own page is linked.

heart failure with preserved ejection fraction, pulmonary hypertension